Covidien Faces Challenge Of Accelerating Growth After Spin-Off From Tyco
This article was originally published in The Gray Sheet
Newly independent medical technology firm Covidien plans select acquisitions and divestitures as well as increased licensing activity to help accelerate growth following its June 29 spin-off from parent company Tyco International
You may also be interested in...
Former Covidien CEO José (Joe) Almeida has been appointed CEO of Baxter as the company zeroes in on its device businesses.
Covidien is now a $9.9 billion, pure-play medical device and supplies company. Separately, the firm could be liable for more than $1 billion in back taxes due to an IRS audit of its former parent, Tyco, though the case is expected to take years to play out in court.
Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.